ÐÓ°ÉÔ­´´

Mytos, based in London, is revolutionizing biotech with fully-automated cell manufacturing. By eliminating traditional manual steps in cell culture and production, Mytos addresses challenges like high labor costs, slow production rates, and human error. Their automated process enhances efficiency and reduces costs, making them a strong market contender. Supported by venture capital firms such as Buckley Ventures, Wing Venture Capital, and IQ Capital Partners, Mytos is well-positioned for growth. Their B2B model enables direct service to biotech companies, enhancing opportunities for partnerships and scalability.